Companies
Sponsors developing CNS drugs — 90 companies across 148compounds in development, with mechanism, indication, and phase for each.54 publicly traded.
- Neurocrine Biosciences, Inc.6 compounds2 Phase 3+
- Alto Neuroscience, Inc.5 compounds
- Merck & Co., Inc.5 compounds
- Axsome Therapeutics, Inc.4 compounds4 Phase 3+
- Biohaven Ltd.4 compounds1 Phase 3+
- Boehringer Ingelheim4 compounds
- Cerevel Therapeutics4 compounds1 Phase 3+
- F. Hoffmann-La Roche Ltd4 compounds
- Johnson & Johnson4 compounds1 Phase 3+
- Otsuka Pharmaceutical Co., Ltd.4 compounds2 Phase 3+
- Taisho Pharmaceutical Co., Ltd.4 compounds1 Phase 3+
- Alkermes plc3 compounds3 Phase 3+
- Eli Lilly and Company3 compounds1 Phase 3+
- Intra-Cellular Therapies, Inc.3 compounds1 Phase 3+
- Vanda Pharmaceuticals Inc.3 compounds3 Phase 3+
- Aelis Farma S.A.2 compounds
- Beckley Psytech Limited2 compounds
- Cortexyme, Inc. (now Quince Therapeutics, Inc.)2 compounds
- Definium Therapeutics, Inc.2 compounds1 Phase 3+
- Gilgamesh Pharmaceuticals, Inc.2 compounds
- Helus Pharma2 compounds1 Phase 3+
- Neumora Therapeutics, Inc.2 compounds
- Relmada Therapeutics, Inc.2 compounds
- Syndeio Biosciences, Inc.2 compounds
- Takeda Pharmaceutical Company Limited2 compounds1 Phase 3+
- Teva Pharmaceutical Industries Ltd.2 compounds1 Phase 3+
- Tonix Pharmaceuticals Holding Corp.2 compounds1 Phase 3+
- Vistagen Therapeutics, Inc.2 compounds1 Phase 3+
- AB Science1 compound1 Phase 3+
- ABVC BioPharma, Inc.1 compound
- AC Immune SA1 compound
- ACADIA Pharmaceuticals Inc.1 compound1 Phase 3+
- AegisCN LLC1 compound
- Alector Inc.1 compound
- Alzamend Neuro, Inc.1 compound
- Apurano Pharmaceuticals GmbH1 compound1 Phase 3+
- Atai Beckley N.V. (AtaiBeckley)1 compound
- Autobahn Therapeutics, Inc.1 compound
- Avanir Pharmaceuticals1 compound
- BioXcel Therapeutics, Inc.1 compound1 Phase 3+
- Cognition Therapeutics, Inc.1 compound
- COMPASS Pathways plc1 compound1 Phase 3+
- Convergence Pharmaceuticals1 compound
- CSPC ZhongQi Pharmaceutical Technology (Shijiazhuang) Co., Ltd.1 compound1 Phase 3+
- Delix Therapeutics, Inc.1 compound
- Draig Therapeutics Ltd1 compound
- Emalex Biosciences Inc.1 compound1 Phase 3+
- Embera NeuroTherapeutics, Inc.1 compound
- EmpathBio, Inc.1 compound
- Engrail Therapeutics, Inc.1 compound
- Gedeon Richter Plc.1 compound
- GH Research PLC1 compound
- Ionis Pharmaceuticals, Inc.1 compound1 Phase 3+
- Karuna Therapeutics1 compound1 Phase 3+
- Kyowa Kirin Co., Ltd.1 compound
- LB Pharmaceuticals Inc.1 compound1 Phase 3+
- Lipocine Inc.1 compound1 Phase 3+
- Luye Pharma Group Ltd.1 compound1 Phase 3+
- MapLight Therapeutics, Inc.1 compound
- Mindset Pharma Inc.1 compound
- Minerva Neurosciences, Inc.1 compound1 Phase 3+
- Mitsubishi Tanabe Pharma Corporation1 compound
- Naurex, Inc.1 compound
- Navitor Pharmaceuticals, Inc.1 compound
- Neuphoria Therapeutics, Inc.1 compound
- NeuroDerm1 compound1 Phase 3+
- Neurotech International Limited1 compound1 Phase 3+
- NeuShen Therapeutics1 compound
- Newron Pharmaceuticals S.p.A.1 compound1 Phase 3+
- Novartis Pharma AG1 compound
- NRx Pharmaceuticals, Inc.1 compound1 Phase 3+
- Pfizer Inc.1 compound
- Pherin Pharmaceuticals, Inc.1 compound
- Principia Biopharma1 compound1 Phase 3+
- Protagenic Therapeutics, Inc.1 compound
- Rapport Therapeutics, Inc.1 compound1 Phase 3+
- Reunion Neuroscience Inc.1 compound
- Reviva Pharmaceuticals Holdings, Inc.1 compound1 Phase 3+
- Sage Therapeutics, Inc.1 compound
- Sanofi1 compound
- Seaport Therapeutics, Inc.1 compound
- Sirtsei Pharmaceuticals, Inc.1 compound
- Spinogenix, Inc.1 compound
- Supernus Pharmaceuticals, Inc.1 compound
- Suven Life Sciences Limited1 compound
- Tetra Discovery Partners1 compound1 Phase 3+
- Theravance Biopharma, Inc.1 compound
- Transcend Therapeutics, Inc.1 compound1 Phase 3+
- Xenon Pharmaceuticals Inc.1 compound1 Phase 3+
- Yangtze River Pharmaceutical Group1 compound1 Phase 3+